15 Jun
2021

$2 billion deal shows growing sophistication of drug royalty sales

Royalty Pharma’s latest investment demonstrates the increasing versatility of drug royalty sales as a means monetising life sciences innovations.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth